243 related articles for article (PubMed ID: 15780738)
21. [Immunogenicity of experimentally combined hepatitis A and hepatitis E vaccine at different dosage ratio].
Dong C; Dai X; Meng JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):130-3. PubMed ID: 17286906
[TBL] [Abstract][Full Text] [Related]
22. [Expression, purification and immunogenicity of a novel hepatitis E virus-like particle].
Dong C; Meng JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 May; 22(3):339-42. PubMed ID: 16643795
[TBL] [Abstract][Full Text] [Related]
23. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine.
Zhang J; Liu CB; Li RC; Li YM; Zheng YJ; Li YP; Luo D; Pan BB; Nong Y; Ge SX; Xiong JH; Shih JW; Ng MH; Xia NS
Vaccine; 2009 Mar; 27(12):1869-74. PubMed ID: 19168109
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells.
Zhang M; Emerson SU; Nguyen H; Engle RE; Govindarajan S; Gerin JL; Purcell RH
Vaccine; 2001 Dec; 20(5-6):853-7. PubMed ID: 11738749
[TBL] [Abstract][Full Text] [Related]
25. Protection of chickens against avian hepatitis E virus (avian HEV) infection by immunization with recombinant avian HEV capsid protein.
Guo H; Zhou EM; Sun ZF; Meng XJ
Vaccine; 2007 Apr; 25(15):2892-9. PubMed ID: 17074425
[TBL] [Abstract][Full Text] [Related]
26. Toward the development of a hepatitis E vaccine.
Kamili S
Virus Res; 2011 Oct; 161(1):93-100. PubMed ID: 21620908
[TBL] [Abstract][Full Text] [Related]
27. A preliminary study on immune response to hepatitis E virus DNA vaccine in mice.
Lu F; Zhuang H; Zhu Y; Zhu X
Chin Med J (Engl); 1996 Dec; 109(12):919-21. PubMed ID: 9275321
[TBL] [Abstract][Full Text] [Related]
28. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.
Tsarev SA; Tsareva TS; Emerson SU; Govindarajan S; Shapiro M; Gerin JL; Purcell RH
Vaccine; 1997 Dec; 15(17-18):1834-8. PubMed ID: 9413090
[TBL] [Abstract][Full Text] [Related]
29. Specific memory B cell response and participation of CD4
Kulkarni SP; Thanapati S; Arankalle VA; Tripathy AS
Vaccine; 2016 Nov; 34(48):5895-5902. PubMed ID: 27997340
[TBL] [Abstract][Full Text] [Related]
30. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4.
Zhou YH; Purcell RH; Emerson SU
Vaccine; 2004 Jun; 22(20):2578-85. PubMed ID: 15193383
[TBL] [Abstract][Full Text] [Related]
31. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine.
Purcell RH; Nguyen H; Shapiro M; Engle RE; Govindarajan S; Blackwelder WC; Wong DC; Prieels JP; Emerson SU
Vaccine; 2003 Jun; 21(19-20):2607-15. PubMed ID: 12744897
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces.
Takahashi M; Yamada K; Hoshino Y; Takahashi H; Ichiyama K; Tanaka T; Okamoto H
Arch Virol; 2008; 153(9):1703-13. PubMed ID: 18679765
[TBL] [Abstract][Full Text] [Related]
34. Varying abilities of recombinant polypeptides from different regions of hepatitis E virus ORF2 and ORF3 to detect anti-HEV immunoglobulin M.
Ma H; Song X; Li Z; Harrison TJ; Zhang H; Huang W; Hao W; Kong W; Wang Y
J Med Virol; 2009 Jun; 81(6):1052-61. PubMed ID: 19382255
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of a hepatitis E vaccine.
Zhang J; Zhang XF; Huang SJ; Wu T; Hu YM; Wang ZZ; Wang H; Jiang HM; Wang YJ; Yan Q; Guo M; Liu XH; Li JX; Yang CL; Tang Q; Jiang RJ; Pan HR; Li YM; Shih JW; Ng MH; Zhu FC; Xia NS
N Engl J Med; 2015 Mar; 372(10):914-22. PubMed ID: 25738667
[TBL] [Abstract][Full Text] [Related]
36. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
[TBL] [Abstract][Full Text] [Related]
37. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus.
Im SW; Zhang JZ; Zhuang H; Che XY; Zhu WF; Xu GM; Li K; Xia NS; Ng MH
Vaccine; 2001 Jun; 19(27):3726-32. PubMed ID: 11395207
[TBL] [Abstract][Full Text] [Related]
38. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
39. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene.
Sominskaya I; Alekseeva E; Skrastina D; Mokhonov V; Starodubova E; Jansons J; Levi M; Prilipov A; Kozlovska T; Smirnov V; Pumpens P; Isaguliants MG
Mol Immunol; 2006 May; 43(12):1941-52. PubMed ID: 16442623
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission.
Zhang Y; Zeng H; Liu P; Liu L; Xia J; Wang L; Zou Q; Wang L; Zhuang H
Vaccine; 2015 Sep; 33(38):4922-8. PubMed ID: 26212003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
